Beyond R-CHOP and the IPI in large-cell lymphoma: Molecular markers as an opportunity for stratification

Current Hematologic Malignancy Reports

Volumn 4, Issue 4, 2009, Pages 218-224

  Westin, Jason R ^a   Fayad, Luis E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FOLINIC ACID; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERCELLULAR ADHESION MOLECULE 1; KI 67 ANTIGEN; METHOTREXATE; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; RITUXIMAB; SURVIVIN; VASCULOTROPIN; VINCRISTINE; VINDESINE;

APOPTOSIS; CLINICAL TRIAL; COMORBIDITY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; EVENT FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; RATING SCALE; REVIEW; TUMOR VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISONE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 70349730030     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0029-y     Document Type: Review

References (58)

1. Harris NL, Jaffe ES, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994, 84: 1361-1392.
2. Swerdlow SH, Campo E, Harris NL, et al.: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, edn 4. Lyon, France: International Agency for Research on Cancer; 2008.
3. McKelvey EM, Gottlieb JA, Wilson HE, et al.: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976, 38: 1484-1493.
4. Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328: 1002-1006.
5. Coiffier B, Haioun C, Ketterer N, et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998, 92: 1927-1932.
6. Vose JM, Link BK, Grossbard ML, et al.: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001, 19: 389-397
7. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 2002, 346: 235-242.
8. Pfreundschuh M, Trümper L, Osterborg A, et al.: CHOPlike chemotherapy plus rituximab versus CHOP-like chemotherapy alone in patients with good-prognosis diffuse large-B-cell lymphoma: A randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7: 379-391.
9. Haberman TM, Weller EA, Morrison VA, et al.: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24: 3121-3127.
10. Reyes F, Lepage E, Ganem G, et al.: ACVBP versus CHOP plus radiotherapy for localized aggresive lymphoma. N Engl J Med 2005, 352: 1197-1205.
11. Pfreundschuh M, Trümper L, Kloess M, et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 2004, 104: 626-633.
12. Cunningham D, Smith P, Mouncey P, et al.: A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma [abstract 8506]. J Clin Oncol 2009, 27(suppl): 15s.
13. Pfreundschuh M, Zeynalova S, Poeschel V, et al.: Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstact 8508]. J Clin Oncol 2008, 26(suppl): Abstract 8508.
14. Rosenberg SA: Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 1977, 61: 1023-1027.
15. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329: 987-994.
16. Sehn LH, Berry B, Chhanabhai M, et al.: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109: 1857-1861.
17. Rodríguez J, Cabanillas F, McLaughlin P, et al.: A proposal for a simple staging system for intermediate grade lymph oma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol 1992, 3: 711-717.
18. Rodriguez J, Pugh WC, Romaguera JE, et al.: Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Ann Oncol 1994, 5: 847-849.
19. Feugier P, Van Hoof A, Sebban C, et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23: 4117-4126.
20. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, et al.: A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: Prognostic impact independent of International Prognostic Index. Br J Haematol 2005, 129: 597-606.
21. Lossos IS, Morgensztern D: Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006, 24: 995-1007.
22. Rimsza LM, Roberts RA, Miller TP, et al.: Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004, 103: 4251-4258.
23. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100: 57-70.
24. Lossos IS, Jones CD, Warnke R, et al.: Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001, 98: 945-951.
25. Winter JN, Weller EA, Horning SJ, et al.: Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood 2006, 107: 4207-4213.
26. Dunleavy K, Davis E, Landgren O, et al.: BCL-6 and rituximab in diffuse large-B cell lymphoma: Where are we? Blood 2007, 109: 843-844.
27. Davis RE, Brown KD, Siebenlist U, et al.: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001, 194: 1861-1874.
28. Filipits M, Jaeger U, Pohl G, et al.: Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma Clin Cancer Res 2002, 8: 729-733.
29. Kramer MH, Hermans J, Wijburg E, et al.: Clinical relevance of BCL-2, BCL-6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998, 92: 3152-3162.
30. Dave SS, Fu K, Wright GW, et al.: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006, 354: 2431-2442.
31. Karsan A, Gascoyne RD, Coupland RW, et al.: Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies. Leuk Lymphoma 1993, 10: 433-441.
32. Martinez A, Bellosillo B, Bosch F, et al.: Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004, 164: 501-510.
33. Adida C, Haioun C, Gaulard P, et al.: Prognostic significance of survivin expression in diffuse large B-cell lymph omas. Blood 2000, 96: 1921-1925.
34. Schlette EJ, Medeiros LJ, Goy A, et al.: Survivin expression predicts poorer prognosis in anaplastic large cell lymphoma. J Clin Oncol 2004, 22: 1682-1688.
35. Salven P, Orpana A, Teerenhovi L, et al.: Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients. Blood 2000, 96: 3712-3718.
36. Lippman SM, Spier CM, Miller TP, et al.: Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol 1990, 3: 361-367.
37. Terol MJ, López-Guillermo A, Bosch F, et al.: Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: Relationship with tumor dissemination and prognostic importance. J Clin Oncol 1998, 16: 35-40.
38. Stauder R, Eisterer W, Thaler J, Günthert U: CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor. Blood 1995, 85: 2885-2899.
39. Tzankov A, Pehrs AC, Zimpfer, et al.: A prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: A tissue microarray analysis of 90 cases. J Clin Pathol 2003, 56: 747-752.
40. Yamaguchi M, Seto M, Okamoto M, et al.: De novo CD5+ diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients. Blood 2002, 99: 815-821.
41. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403: 503-511.
42. Rosenwald A, Wright G, Leroy K, et al.: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198: 851-862.
43. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346: 1937-1947.
44. Shipp MA, Ross KN, Tamayo P, et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002, 8: 68-74.
45. Lossos IS, Czerwinski DK, Alizadeh AA, et al.: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004, 350: 1828-1837.
46. Lenz G, Wright G, Dave SS, et al.: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359: 2313-2323.
47. Li C, Kim SW, Rai D, et al.: Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 2009, 113: 6681-6690.
48. Fu K, Weisenburger DD, Choi WW, et al.: Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like, and the non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008, 26: 4587-4594.
49. Hans CP, Weisenburger DD, Greiner TC, et al.: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103: 275-282.
50. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al.: Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007, 109: 4930-4935.
51. Rossi D, Rasi S, Franceschetti S, et al.: Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 2009, 23: 1118-1126.
52. Terasawa T, Lau J, Bardet S, et al.: Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: A systematic review. J Clin Oncol 2009, 27: 1906-1914.
53. Itti E, Lin C, Dupuis J, et al.: Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009, 50: 527-533.
54. Mikhaeel NG, Hutchings M, Fields PA, et al.: FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005, 16: 1514-1523.
55. Meignan M, Gallamini A, Haioun C: Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009, 50: 1257-1260.
56. Natkunam Y, Farinha P, Hsi ED, et al.: LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008, 26: 447-454.
57. Evens AM, Schumacker PT, Helenowski IB, et al.: Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol 2008, 141: 676-680.
58. Pazgal I, Boycov O, Shpilberg O, et al.: Expression of VEGFC, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas. Leuk Lymphoma 2007, 48: 2213-2220.